Breast Cancer | Clinical

Study of CRX100 Makes Progress in Patients With Refractory Solid Tumors

March 05, 2021

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

Exploring When to Use Neoadjuvant Treatment in TNBC

March 04, 2021

Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.

FDA Issues CRL for Oral Paclitaxel and Encequidar for Metastatic Breast Cancer

March 01, 2021

The FDA has issued a complete response letter to Athenex, Inc, regarding the New Drug Application for oral paclitaxel in combination with encequidar for the treatment of metastatic breast cancer. The FDA stated that the application review process has been completed, but the NDA is not ready for approval due to safety and efficacy concerns.

Can CDK4/6 Inhibitors Be Optimized for Breast Cancer?

February 25, 2021

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

Olaparib Prolongs Invasive Disease-Free Survival in BRCA-Mutant, HER2- Breast Cancer

February 19, 2021

Patients with BRCA-mutated high-risk HER2-negative early breast cancer demonstrated a superior invasive disease-free survival when compared with placebo in the phase 3 OlympiA trial.

ODAC Votes to Wait on Neoadjuvant Pembrolizumab Approval in High-Risk TNBC

February 10, 2021

In a 10 to 0 vote, the FDA’s Oncology Drug Advisory Committee did not support the approval of pembrolizumab (Keytruda) in combination with chemotherapy as neoadjuvant therapy for high-risk, early-stage triple-negative breast cancer.

Long-Term Results Show Comparable Efficacy for Anastrozole and Tamoxifen

January 26, 2021

Halle Moore, MD, discusses the results of the IBIS-II DCIS trial of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ.

MBCC Offers Review of Burgeoning Advancements in Breast Cancer Management

January 24, 2021

The virtual 38th Annual Miami Breast Cancer Conference®, hosted by Physicians’ Education Resource®, LLC will feature presentations from industry thought leaders on innovations in the arena of breast cancer treatment, including topics about systemic therapy and beyond.

Emerging ESR1-Targeted Therapy Added to Abemaciclib to Treat Metastatic ER+/HER2– Breast Cancer

January 22, 2021

In an interview with Targeted Oncology, Senthil Damodaran, MD, PhD, discussed the need for an ESR1-targeted agent for the postmenopausal women with ESR1-positive, locally advanced or metastatic ER-positive/HER2-negative breast cancer.

HER2+ BC: A Year in Review and Updates from SABCS

January 19, 2021

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.